Possible donor-dependent differences in efficacy of fresh frozen plasma for treatment of ACE inhibitor–induced angioedema
- 1 July 2019
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (6) , 2087-2088
Abstract
No abstract availableFunding Information
- National Institutes of Health
- Institute of Translational Health Sciences, University of Washington (UL1TR002345)
- National Center for Advancing Translational Sciences
This publication has 9 references indexed in Scilit:
- Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor–associated angioedemaJournal of Allergy and Clinical Immunology, 2018
- Novel Therapies for Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Systematic Review of Current EvidenceThe Journal of Emergency Medicine, 2017
- Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway AngioedemaThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedemaJournal of Allergy and Clinical Immunology, 2017
- Angiotensin-converting enzyme inhibitor–induced angioedema worsened with fresh frozen plasmaThe American Journal of Emergency Medicine, 2017
- Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular diseaseNephrology Dialysis Transplantation, 2015
- Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-BradykininThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Nonadherence with angiotensin-converting enzyme inhibitor therapyJACC, 1999
- Plasma bradykinin in angio-oedemaThe Lancet, 1998